[Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
CDDP is often dose-limited owing to its nephrotoxicity. Urinary NAG was measured to evaluate the nephrotoxicity of CDDP in 18 patients (DIV: 12 patients, Intra-Peritoneal: 6 patients) with or without Fosfomycin. The gradual increase in urinary NAG activity was noted on repeating the therapy. 24 hour NAG excretion was correlated with that of urinary beta 2-microglobulin. However, urinary NAG was not correlated with Ccr 24 or BUN. Though Ccr 24 and BUN were normal, urinary NAG and beta 2-microglobulin markedly increased during CDDP therapy. Fosfomycin administration significantly decreased urinary NAG, which was increased by CDDP. These results indicate that: The measurement of urinary NAG and beta 2-microglobulin are most useful in estimating the nephrotoxicity of CDDP. Fosfomycin decreases the nephrotoxicity of CDDP.
D000118:Acetylglucosaminidase / Q000652:urine*; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D006596:Hexosaminidases / Q000652:urine*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy
D005578:Fosfomycin; D006596:Hexosaminidases; D000118:Acetylglucosaminidase; D002945:Cisplatin